Literature DB >> 32099345

Minimal Clinically Important Differences for Patient-Reported Outcome Measures of Cough and Sputum in Patients with COPD.

Patrícia Rebelo1,2, Ana Oliveira1,2, Cátia Paixão1,2, Carla Valente3, Lília Andrade3, Alda Marques1,2.   

Abstract

Background: Cough and sputum are highly prevalent in patients with chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) has shown to be effective in managing these symptoms. However, the interpretation of the magnitude of PR effects is hindered by the lack of minimal clinically important differences (MCIDs). Purpose: This study established MCIDs for the Leicester cough questionnaire (LCQ) and the cough and sputum assessment questionnaire (CASA-Q), in patients with COPD after PR. Patients and
Methods: An observational prospective study was conducted in patients with COPD who participated in a 12-weeks community-based PR program. Anchor- (mean change, receiver operating characteristic curves and linear regression analysis) and distribution-based methods [0.5*standard deviation; standard error of measurement (SEM); 1.96*SEM; minimal detectable change and effect size] were used to compute the MCIDs. The anchors used were: i) patients and physiotherapists global rating of change scale, ii) COPD assessment test, iii) St. George's respiratory questionnaire and iv) occurrence of an exacerbation during PR. Pooled MCIDs were computed using the arithmetic weighted mean (2/3 for anchor- and 1/3 for distribution-based methods).
Results: Forty-nine patients with COPD (81.6% male, 69.8±7.4years, FEV150.4±19.4%predicted) were used in the analysis. The pooled MCIDs were 1.3 for LCQ and for CASA-Q domains were: 10.6 - cough symptoms; 10.1 - cough impact; 9.5 - sputum symptoms and 7.8 - sputum impact.
Conclusion: The MCIDs found in this study are potential estimates to interpret PR effects on cough and sputum, and may contribute to guide interventions.
© 2020 Rebelo et al.

Entities:  

Keywords:  COPD; measurement characteristics; patient health questionnaire; pulmonary rehabilitation; statistics; symptoms

Mesh:

Year:  2020        PMID: 32099345      PMCID: PMC6996113          DOI: 10.2147/COPD.S219480

Source DB:  PubMed          Journal:  Int J Chron Obstruct Pulmon Dis        ISSN: 1176-9106


  67 in total

Review 1.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Authors:  Dennis Revicki; Ron D Hays; David Cella; Jeff Sloan
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

Review 2.  Is cough important in acute exacerbations of COPD?

Authors:  Michael G Crooks; Timothy Brown; Alyn H Morice
Journal:  Respir Physiol Neurobiol       Date:  2018-02-10       Impact factor: 1.931

Review 3.  Cough and sputum production as risk factors for poor outcomes in patients with COPD.

Authors:  Marc Miravitlles
Journal:  Respir Med       Date:  2011-02-25       Impact factor: 3.415

Review 4.  Pulmonary rehabilitation for chronic obstructive pulmonary disease.

Authors:  Bernard McCarthy; Dympna Casey; Declan Devane; Kathy Murphy; Edel Murphy; Yves Lacasse
Journal:  Cochrane Database Syst Rev       Date:  2015-02-23

5.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Authors:  J C Bestall; E A Paul; R Garrod; R Garnham; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 6.  Morning symptoms in COPD: a treatable yet often overlooked factor.

Authors:  Amanda R van Buul; Marise J Kasteleyn; Niels H Chavannes; Christian Taube
Journal:  Expert Rev Respir Med       Date:  2017-03-22       Impact factor: 3.772

7.  Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.

Authors:  Brigitta U Monz; Paul Sachs; Jeffrey McDonald; Bruce Crawford; Michael C Nivens; Kay Tetzlaff
Journal:  Respir Med       Date:  2009-11-14       Impact factor: 3.415

8.  The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute).

Authors:  Nadia Yousaf; Kai K Lee; Bhagyashree Jayaraman; Ian D Pavord; Surinder S Birring
Journal:  Cough       Date:  2011-07-18

9.  Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease.

Authors:  Judith J Stephenson; Qian Cai; Michelle Mocarski; Hiangkiat Tan; Jalpa A Doshi; Sean D Sullivan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-17

10.  Enhancing our understanding of the time course of acute exacerbations of COPD managed on an outpatient basis.

Authors:  Ana Oliveira; Vera Afreixo; Alda Marques
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-20
View more
  3 in total

1.  Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.

Authors:  Joao A de Andrade; Tejaswini Kulkarni; Megan L Neely; Anne S Hellkamp; Amy Hajari Case; Daniel A Culver; Kalpalatha Guntupalli; Shaun Bender; Craig S Conoscenti; Laurie D Snyder
Journal:  Respir Res       Date:  2022-01-07

2.  Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry.

Authors:  Hyun J Kim; Laurie D Snyder; Megan L Neely; Anne S Hellkamp; David L Hotchkin; Lake D Morrison; Shaun Bender; Thomas B Leonard; Daniel A Culver
Journal:  Lung       Date:  2022-01-07       Impact factor: 2.584

3.  Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.

Authors:  Alyn Morice; Jaclyn A Smith; Lorcan McGarvey; Surinder S Birring; Sean M Parker; Alice Turner; Thomas Hummel; Isabella Gashaw; Lueder Fels; Stefan Klein; Klaus Francke; Christian Friedrich
Journal:  Eur Respir J       Date:  2021-11-18       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.